Abstract: Rabeximod compounds selected from HCl salts, methane sulphonic acid salts and malonic acid salts of Rabeximod. Also, a pharmaceutical composition including a Rabeximod compound, and optionally a pharmaceutically acceptable additive. Further, a method for treatment of a mammal, such as a human subject, suffering from or diagnosed with rheumatoid arthritis, preferably moderate rheumatoid arthritis, severe rheumatoid arthritis or moderate to severe rheumatoid arthritis. The method includes administering to the mammal subject an amount of a Rabeximod compound effective to treat the rheumatoid arthritis.

Abstract: The present invention relates to therapeutic uses of compositions comprising 9-Chloro-2,3-dimethyl-6-(N,N-dimethylaminoethylamino-2-oxoethyl)-6H-indolo-[2,3-b]quinoxaline in the treatment of human subjects suffering from Rheumatoid Arthritis.